Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
作者信息
Morschhauser Franck, Dyer Martin J S, Walter Harriet S, Danilov Alexey V, Ysebaert Loic, Hodson Daniel James, Fegan Christopher, Rule Simon A, Radford John, Cartron Guillaume, Bouabdallah Krimo, Davies Andrew John, Spurgeon Stephen, Rajakumaraswamy Nishanthan, Li Biao, Humeniuk Rita, Huang Xi, Bhargava Pankaj, Jürgensmeier Juliane M, Salles Gilles
机构信息
Univ. Lille, CHU Lille, ULR 7365, GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.
Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK.
出版信息
Leukemia. 2021 Jul;35(7):2108-2113. doi: 10.1038/s41375-020-01108-x. Epub 2020 Dec 17.
Abstract
摘要
相似文献
1
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.替拉鲁替尼联合idelalisib或恩托司替尼治疗既往治疗的B细胞淋巴瘤的1b期研究。
Leukemia. 2021 Jul;35(7):2108-2113. doi: 10.1038/s41375-020-01108-x. Epub 2020 Dec 17.
2
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.替拉鲁替尼联合伊德拉利西布或恩特索利替尼治疗既往治疗的慢性淋巴细胞白血病的 Ib 期研究。
Clin Cancer Res. 2020 Jun 15;26(12):2810-2818. doi: 10.1158/1078-0432.CCR-19-3504. Epub 2020 Mar 10.
3
Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.血液系统癌症：idelalisib靶向B细胞恶性肿瘤患者的PI3Kδ
Nat Rev Clin Oncol. 2014 Apr;11(4):184-6. doi: 10.1038/nrclinonc.2014.42. Epub 2014 Mar 18.
4
Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.依鲁替尼治疗惰性 B 细胞恶性肿瘤的疗效和安全性。
Expert Opin Pharmacother. 2020 Oct;21(15):1915-1926. doi: 10.1080/14656566.2020.1791083. Epub 2020 Jul 20.
5
Idelalisib for the treatment of non-Hodgkin lymphoma.idelalisib用于治疗非霍奇金淋巴瘤。
Expert Opin Pharmacother. 2016;17(2):265-74. doi: 10.1517/14656566.2016.1135130. Epub 2016 Jan 28.
6
Idelalisib for chronic lymphocytic leukemia.idelalisib用于治疗慢性淋巴细胞白血病。
Clin Adv Hematol Oncol. 2014 Dec;12(12):846-8.
7
Idelalisib, ibrutinib show benefits in CLL.idelalisib和ibrutinib在慢性淋巴细胞白血病中显示出疗效。
Cancer Discov. 2014 Apr;4(4):382. doi: 10.1158/2159-8290.CD-NB2014-025. Epub 2014 Feb 20.
8
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.靶向肿瘤性B细胞并利用微环境：依鲁替尼和idelalisib的“双面性”
J Hematol Oncol. 2015 May 29;8:60. doi: 10.1186/s13045-015-0157-x.
9
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.依鲁替尼和艾代拉里斯对慢性淋巴细胞白血病个体及社会层面治疗药物成本的影响。
J Oncol Pract. 2015 May;11(3):252-8. doi: 10.1200/JOP.2014.002469. Epub 2015 Mar 24.
10
Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.idelalisib用于复发/难治性惰性B细胞非霍奇金淋巴瘤：药代动力学及临床试验结果概述
Expert Rev Hematol. 2015 Oct;8(5):581-93. doi: 10.1586/17474086.2015.1071663.
引用本文的文献
1
Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions.针对癌症治疗中小分子抑制剂的 PI3K 家族：当前临床现状和未来方向。
Mol Cancer. 2024 Aug 10;23(1):164. doi: 10.1186/s12943-024-02072-1.
2
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.泽布替尼联合zanubrutinib 治疗既往治疗的滤泡性和套细胞淋巴瘤的安全性和有效性。
Br J Haematol. 2024 May;204(5):1762-1770. doi: 10.1111/bjh.19419. Epub 2024 Mar 19.
3
Development and safety of PI3K inhibitors in cancer.PI3K 抑制剂在癌症中的研发与安全性。
Arch Toxicol. 2023 Mar;97(3):635-650. doi: 10.1007/s00204-023-03440-4. Epub 2023 Feb 11.
4
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.双重 BTK/SYK 抑制联合 CG-806（芦可替尼）可破坏套细胞淋巴瘤中 B 细胞受体和 Bcl-2 信号网络。
Cell Death Dis. 2022 Mar 16;13(3):246. doi: 10.1038/s41419-022-04684-1.
5
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.Copanlisib联合依鲁替尼治疗复发/难治性套细胞淋巴瘤的1期试验。
Blood Adv. 2022 Sep 27;6(18):5262-5266. doi: 10.1182/bloodadvances.2021006555.
6
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.布鲁顿酪氨酸激酶抑制剂在 B 细胞恶性肿瘤中的应用及其特点。
Target Oncol. 2022 Jan;17(1):69-84. doi: 10.1007/s11523-021-00857-8. Epub 2021 Dec 14.
7
Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.半机械论 PK/PD 模型与模拟不可逆 BTK 抑制作用，支持替拉鲁替尼在 RA 受试者中的剂量选择。
Clin Pharmacol Ther. 2022 Feb;111(2):416-424. doi: 10.1002/cpt.2439. Epub 2021 Oct 27.
8
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.Buparlisib 和 Ibrutinib 联合治疗伴有连续游离细胞 DNA 监测的套细胞淋巴瘤、滤泡性淋巴瘤和弥漫性大 B 细胞淋巴瘤的疗效和安全性的 I/ Ib 期研究。
Clin Cancer Res. 2022 Jan 1;28(1):45-56. doi: 10.1158/1078-0432.CCR-21-2183. Epub 2021 Oct 6.
Zotero 插件